Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Exousia Bio (LMMY) EPS (Weighted Average and Diluted) (2022 - 2025)

Lamy (LMMY) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.0 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 113.59% to -$0.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.0 through Nov 2025, down 113.59% year-over-year, with the annual reading at $0.01 for FY2025, 299.15% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.0 in Q4 2025 for Lamy, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q4 2024 to a low of -$0.0 in Q2 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.0 across 4 years, with a median of -$0.0 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 2342.63% in 2024 and later crashed 713.45% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then surged by 69.64% to -$0.0 in 2023, then surged by 2342.63% to $0.01 in 2024, then plummeted by 113.59% to -$0.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LMMY at -$0.0 in Q4 2025, -$0.0 in Q3 2025, and -$0.0 in Q2 2025.